ClinicalTrials.gg
Enrolling by invitationNCT06637293DAISEA-ECGUpdated Oct 8, 2026

Deployment and Evaluation of Artificial Intelligence Software for Electrocardiogram Analysis and Management in Primary Care

An interventional study of DeepECG plateform diagnosis & recommendations in Primary Care Provider and Structural Heart Disease, sponsored by Montreal Heart Institute. Enrolling by invitation at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Montreal Heart Institute · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 8, 2026Now Enrolling by invitationStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The DAISEA-ECG project aims to improve the diagnosis of heart diseases in primary care through the DeepECG platform, which combines ECG-AI and ECHONeXT algorithms. This study uses a stepped wedge design, where each Family Medicine Group acts as its own control. The FMGs will gradually transition from the control period (without AI recommendations) to the intervention period (with AI recommendations activated) in a randomized sequence.

The primary objective is to compare the sensitivity of family physicians in detecting cardiac pathologies, with and without the assistance of the DeepECG platform. Sensitivity is defined as the proportion of patients correctly referred to cardiology or for transthoracic echocardiography (TTE) among those who indeed required cardiovascular evaluation, as confirmed by an independent adjudication committee.

Read the detailed description

Mathematically, sensitivity is calculated as True Positive / (True Positive + False Negative), where True Positive represents correctly referred patients and false negatives represents patients who should have been referred but were not.

The secondary objectives include determining the rate of cardiovascular evaluation referrals before and after the intervention (implementation of the DeepECG platform), the individual characteristics of the intervention (PPV, NPV, and specificity), as well as evaluating the feasibility of implementing AI-based automatic ECG interpretation in primary care through surveys of family physicians and cardiologists.

PPV: Positive predictive value NPV: Negative predictive value

02

Conditions studied

  • Primary Care Provider
  • Structural Heart Disease
03

In context

Lead sponsor

Montreal Heart Institute is the lead sponsor of 101 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Family Physicians or Nurse Practitioners

Family physicians or nurse practitioners (NPs) practicing in one of the participating FMGs.

Family physicians who have given their free and . Patients

Adult patients (18 years or older). Patients without follow-up in cardiology or internal medicine for cardiovascular issues (arrhythmia, heart failure, myocardial infarction, atherosclerotic coronary artery disease, valvular heart disease) or those who had a negative investigation in the past with no additional follow-up.

Any 12-lead ECG performed with the MUSE GE 360 machine. ECG of adequate technical quality for interpretation (otherwise, it will be automatically rejected by the platform).

-

Exclusion criteria

Exclusion Criteria:

  • Family Physicians or Nurse Practitioners

Family physicians practicing exclusively in pediatrics (patients under 18 years old).

Family physicians unable to follow the project guidelines.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,000 participants (estimated)

Study arms

  • No intervention
    No DeepECG plateform diagnosis & recommendations
  • Experimental
    DeepECG plateform diagnosis & recommendations

    Device: DeepECG plateform diagnosis & recommendations

Interventions

  • DeviceDeepECG plateform diagnosis & recommendations

    EchoNeXT\& ECG-AI algorithm

06

What researchers measure

Primary outcomes

  1. sensitivity of cardiology referrals

    Compare the sensitivity of cardiology referrals made by family physicians and nurse practitioners before and after the activation of AI-assisted diagnostics and recommendations from the DeepECG platform.

    Time frame: 18 months

Secondary outcomes

  1. specificity, negative predictive value, and positive predictive value of cardiology referrals

    Compare the specificity, negative predictive value, and positive predictive value of cardiology referrals made by family physicians and nurse practitioners before and after the activation of AI-assisted diagnostics and recommendations.

    Time frame: 18 months

07

Study locations

1 site
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jan 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Oct 2, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 8, 2026
Start date
Oct 6, 2025→Oct 2, 2025 (actual)
Oct 8, 2026
Contact
No study contact listed any more: removed r•••@gmail.com · •••3330; removed m•••@icm-mhi.org · •••3330
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Montreal Heart Institute · Montreal, CanadaContact removed m•••@icm-mhi.org · •••3330Contact removed (no phone or email listed)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Oct 6, 2025→Oct 2, 2025 (now actual)
    Contact No study contact listed any more: removed r•••@gmail.com · •••3330; removed m•••@icm-mhi.org · •••3330
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Montreal Heart Institute · Montreal, CanadaContact removed m•••@icm-mhi.org · •••3330Contact removed (no phone or email listed)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06637293
Responsible party
Robert Avram (Interventional cardiologist, Montreal Heart Institute) — Principal investigator
First posted
Oct 15, 2024
Start date
Oct 2, 2025
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion